A pilot study to investigate how best to integrate a PET-CT scan into the radiotherapy planning pathway for lymphoma

Not Applicable

Completed

• Conditions: High grade lymphoma; Cancer

• Registration Number: ISRCTN46587767
• Lead Sponsor: eeds Teaching Hospitals NHS Trust

Brief Summary

2018 Results article in https://pubmed.ncbi.nlm.nih.gov/30246160/ (added 10/07/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-06-28
• Study Completion: 2017-12-31
• Last Update Posted: 25 July 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

1. Age =18 years
2. WHO Performance status 0-2 (Appendix A)
3. Histologically proven Hodgkin lymphoma or high grade non-Hodgkin lymphoma
4. Ann Arbor Stage I/II disease based upon clinical examination and any radiology investigations performed
5. Clinical decision to proceed with sequential chemotherapy and radiotherapy if stage I/II disease is confirmed on subsequent PET-CT staging
6. Residual disease in situ after biopsy (either palpable or on any imaging acquired pre-PET-CT)
7. Able to provide fully informed written consent
8. Able to lie flat for 1 hour
9. Not be pregnant or breast feeding. Female patients of childbearing potential must agree to use effective contraception, be surgically sterile, or be post-menopausal

Exclusion Criteria

1. Hypersensitivity to 18Fluorine-FDG
2. Hypersensitivity to iodinated contrast media
3. Poorly controlled diabetes
4. Acute renal failure or moderate renal impairment (estimated glomerular filtration rate < 30 mL/min)
5. Uncontrolled pain
6. Urinary incontinence
7. Female patients must not be pregnant and if of child bearing age using adequate contraception
8. Breast feeding
9. Serious psychiatric comorbidity

Study & Design

• Study Type: Interventional
• Study Design: Not specified